Innova Captab: Inventory High, ROCE Low – Still Worth ₹867?

🧠 At a Glance

Innova Captab is an integrated pharma company with ₹1,244 Cr in FY25 revenue, ₹128 Cr profit, and a 15% EBITDA margin. It boasts 36% profit CAGR over 5 years and a growing CDMO business, but rising inventory, declining ROCE, and no dividend payout raise questions. Stock trades at 39x P/E.

🎬 1. Intro — “CDMO Champ or Just a Capital Junkie?”

Innova Captab came into the public market as a pharma growth machine:

• Strong CDMO biz 💊
• High-profile clients (Cipla, Mankind, etc.) 🤝
• Plants across Himachal & new Jammu facility 🏭
• ₹1,244 Cr in sales, ₹128 Cr in FY25 PAT 🚀

But now it’s:

• Sitting on 119 inventory days
• Showing falling ROCE (from 31% to 15%)
• Offering zero dividends
• And still priced at 39x earnings

So… time to dissect whether this stock is a healthier version of IPCA or a cash-burning placebo.

🧪 2. WTF Do They Even Do? (Business Model)

Innova Captab operates across 3 key pharma verticals:

1. CDMO / Contract Manufacturing (B2B) – Their bread and butter
   • Supplies formulations to big brands like Cipla, Lupin, Zydus
   • 9 plants with capacity across tablets, capsules, ointments, syrups
2. Own Brands (B2C) – Growing gradually
   • Focus on therapeutic areas like pain relief, cold & cough, anti-infectives
3. Export Business – Present in 20+ countries
   • Regulated + semi-regulated markets

👉 CDMO =